TAE Life Sciences

Founded in 2017 in the US, TAE Life Sciences focuses on developing boron neutron capture therapy (BNCT) for treating cancerous tumors. The company has successfully completed 2 deals, with the most recent occurring on June 2, 2020.TAE Life Sciences specializes in the development of biologically targeted radiation therapies, with a key focus on boron neutron capture therapy (BNCT). This therapy is designed to treat cancerous tumors effectively while preserving the surrounding healthy tissues. It works by delivering boron-10 drugs directly to cancer cells, using a low-energy neutron beam to create alpha particles that destroy tumor cells. The company aims to assist patients suffering from recurrent, invasive, untreatable, and metastatic cancers, offering a treatment that can be completed in one to two sessions.TAE Life Sciences generates revenue through partnerships and collaborations with healthcare institutions and research organizations. Their B2B transactions typically involve hospitals integrating the BNCT technology into their treatment protocols, which includes initial setup fees for the Alphabeam™ Neutron System and ongoing agreements for boron-10 drugs and maintenance services. As their products are still in development and not commercially available, specific pricing models remain undisclosed. They are designing new products aimed at further enhancing their BNCT offerings. Additionally, the company seeks to expand into new geographic markets, specifically focusing on regions with high demand for advanced cancer therapies. Specific timelines for product launches and market entry strategies will be determined as they progress with their current initiatives.

1. Series B

   Jun 2, 2020

   Amount

   $30M

   Investors

   Locked

2. Series A

   Mar 12, 2018

   Amount

   $40M

   Investors

   Locked